GoKawiilAtaiBeckley Reports Toad-Venom Nasal Spray Eases Treatment-Resistant Depression in Trial
AtaiBeckley, a subsidiary linked to Eli Lilly, has completed a double-blind randomized clinical trial of a nasal spray containing mebufotenin, a psychedelic compound derived from Sonoran Desert toad venom. The study, published in the Journal of the American Medical Association, involved 193 adults with treatment-resistant depression and tested 8mg and 12mg doses of the spray. Researchers described the compound as showing potential as an effective, well-tolerated therapy with a rapid recovery time.